Ieni A, Barresi V, Branca G, Giuffrè G, Rosa M A, Tuccari G
Department of Human Pathology, Section of Pathological Anatomy, University of Messina, Messina, Italy ;
Oncol Lett. 2013 May;5(5):1536-1540. doi: 10.3892/ol.2013.1227. Epub 2013 Mar 5.
Although the immunohistochemical presence of lactoferrin (LF) in pathological neoplastic bone and cartilage samples has previously been studied, no data concerning the distribution of LF in bone metastases of cancers that have originated from different organs are available at present. Consequently, using a monoclonal antibody, we have investigated the immunohistochemical LF pattern in 50 formalin-fixed and paraffin-embedded samples of human bone metastases and their corresponding primary carcinoma tumours (breast, 8; prostate, 4; kidney, 4; lung, 3; colon-rectum, 2 and uterus, 4). Quantification of LF immunoreactivity was performed using an intensity distribution (ID) score. LF immuno staining with a variable ID score was encountered in 11/25 (44%) metastatic lesions. In particular, the LF immunoreactivity was identified with a percentage ranging from 50 to 75% of bone metastases due to prostatic, renal, uterine and colorectal carcinomas; the positivity decreased in breast carcinomas (37.5%) and was completely absent in lung cancers. No differences in the LF-ID score were observed between primary and metastatic neoplastic localisations. Additionally, no correlations were identified between LF immunoexpression and the other parameters tested, including the age and gender of patients. Regardless of the mechanism of action of LF in human malignant tumours, we identified LF immunohistochemical reproducibility at primary and metastatic sites. Therefore, we hypothesise that the presence of LF in native neoplastic carcinomatous clones is maintained in secondary bone metastatic deposits.
尽管此前已对病理性肿瘤性骨和软骨样本中乳铁蛋白（LF）的免疫组化存在情况进行过研究，但目前尚无关于源自不同器官的癌症骨转移中LF分布的数据。因此，我们使用一种单克隆抗体，对50例福尔马林固定、石蜡包埋的人骨转移样本及其相应的原发性癌肿瘤（乳腺癌8例；前列腺癌4例；肾癌4例；肺癌3例；结直肠癌2例；子宫癌4例）的免疫组化LF模式进行了研究。使用强度分布（ID）评分对LF免疫反应性进行定量。在11/25（44%）的转移病灶中发现了ID评分可变的LF免疫染色。特别是，在前列腺癌、肾癌、子宫癌和结直肠癌导致的骨转移中，LF免疫反应性的百分比范围为50%至75%；在乳腺癌中阳性率下降（37.5%），而在肺癌中则完全不存在。在原发性和转移性肿瘤定位之间未观察到LF-ID评分的差异。此外，未发现LF免疫表达与所测试的其他参数之间存在相关性，包括患者的年龄和性别。无论LF在人类恶性肿瘤中的作用机制如何，我们都在原发性和转移部位确定了LF免疫组化的可重复性。因此，我们推测在天然肿瘤性癌克隆中存在的LF在继发性骨转移沉积物中得以保留。
